35 related articles for article (PubMed ID: 30131294)
1. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008).
Wahlgren T; Harmenberg U; Sandström P; Lundstam S; Kowalski J; Jakobsson M; Sandin R; Ljungberg B
Br J Cancer; 2013 Apr; 108(7):1541-9. PubMed ID: 23531701
[TBL] [Abstract][Full Text] [Related]
2. The impact of body mass index on oncological and surgical outcomes of patients undergoing nephrectomy: a systematic review and meta-analysis.
Ong CSH; Law TYX; Mok A; Ho KSC; Wang Z; Chiong E; Tiong HY; Teoh JYC
BJU Int; 2023 Dec; 132(6):608-618. PubMed ID: 37401806
[TBL] [Abstract][Full Text] [Related]
3. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study.
Beisland C; Johannesen TB; Klepp O; Axcrona U; Torgersen KM; Kowalski J; Solli O; Sandin R; Oldenburg J
Onco Targets Ther; 2017; 10():371-385. PubMed ID: 28144152
[TBL] [Abstract][Full Text] [Related]
4. Circulating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort.
Muller DC; Fanidi A; Midttun Ø; Steffen A; Dossus L; Boutron-Ruault MC; Severi G; Kühn T; Katzke V; de la Torre RA; González CA; Sánchez MJ; Dorronsoro M; Santiuste C; Barricarte A; Khaw KT; Wareham N; Travis RC; Trichopoulou A; Giotaki M; Trichopoulos D; Palli D; Krogh V; Tumino R; Vineis P; Panico S; Tjønneland A; Olsen A; Bueno-de-Mesquita HB; Peeters PH; Ljungberg B; Wennberg M; Weiderpass E; Murphy N; Riboli E; Ueland PM; Boeing H; Brennan P; Johansson M
Am J Epidemiol; 2014 Oct; 180(8):810-20. PubMed ID: 25205830
[TBL] [Abstract][Full Text] [Related]
5. Serum antibodies against Saccharomyces cerevisiae: a new prognostic indicator in metastatic renal-cell carcinoma.
Ramoner R; Rahm A; Gander H; Stollenwerk B; Falkensammer C; Leonhartsberger N; Thurnher M
Cancer Immunol Immunother; 2008 Aug; 57(8):1207-14. PubMed ID: 18322685
[TBL] [Abstract][Full Text] [Related]
6. Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time.
Ali A; Adams DL; Kasabwala DM; Tang CM; Ho TH
Sci Rep; 2023 Jun; 13(1):10544. PubMed ID: 37386095
[TBL] [Abstract][Full Text] [Related]
7. The impact of the COVID-19 pandemic on renal cancer care.
Yildirim H; Bins AD; van den Hurk C; van Moorselaar RJA; van Oijen MGH; Bex A; Zondervan PJ; Aben KKH
World J Urol; 2024 Apr; 42(1):231. PubMed ID: 38613582
[TBL] [Abstract][Full Text] [Related]
8. The effect of hyperlipidemia on overall survival in patients with cancer was differentiated by BMI and hyperlipidemia type.
Tian HY; Yang M; Xie HL; Ruan GT; Ge YZ; Zhang XW; Zhang HY; Liu CA; Liu T; Shi HP
Nutr Metab (Lond); 2024 Jun; 21(1):37. PubMed ID: 38914993
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.
Marschner N; Knauf W
Oncol Res Treat; 2024 Mar; ():1-11. PubMed ID: 38493778
[TBL] [Abstract][Full Text] [Related]
10. Regional outcome disparities in German head and neck cancer patients: Shorter survival in Eastern Germany.
Vahl JM; Nagel G; Abou Kors T; Brand M; von Witzleben A; Sonntag M; Grages A; Theodoraki MN; Greve J; Denkinger M; Dallmeier D; Idel C; Stilgenbauer S; Hoffmann TK; Laban S
Cancer Med; 2023 Dec; 12(23):21426-21435. PubMed ID: 38037808
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK; Powles T; Burotto M; Escudier B; Bourlon MT; Zurawski B; Oyervides Juárez VM; Hsieh JJ; Basso U; Shah AY; Suárez C; Hamzaj A; Goh JC; Barrios C; Richardet M; Porta C; Kowalyszyn R; Feregrino JP; Żołnierek J; Pook D; Kessler ER; Tomita Y; Mizuno R; Bedke J; Zhang J; Maurer MA; Simsek B; Ejzykowicz F; Schwab GM; Apolo AB; Motzer RJ;
N Engl J Med; 2021 Mar; 384(9):829-841. PubMed ID: 33657295
[TBL] [Abstract][Full Text] [Related]
12. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of pan-immune-inflammation value and body mass index in geriatric patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first line treatment. A single-center retrospective study.
Domański P; Jarosińska J; Kruczyk B; Piętak M; Mydlak A; Demkow T; Kuncman Ł; Darewicz M; Sikora-Kupis B; Michalski W; Kucharz J
Contemp Oncol (Pozn); 2023; 27(4):242-248. PubMed ID: 38405212
[TBL] [Abstract][Full Text] [Related]
15. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.
Cortellini A; Bersanelli M; Buti S; Cannita K; Santini D; Perrone F; Giusti R; Tiseo M; Michiara M; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Rastelli F; Pergolesi F; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; De Giglio A; Iacono D; Gelibter A; Occhipinti MA; Parisi A; Porzio G; Fargnoli MC; Ascierto PA; Ficorella C; Natoli C
J Immunother Cancer; 2019 Feb; 7(1):57. PubMed ID: 30813970
[TBL] [Abstract][Full Text] [Related]
16. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
[TBL] [Abstract][Full Text] [Related]
17. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
18. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry.
Marschner N; Staehler M; Müller L; Nusch A; Harde J; Koska M; Jänicke M; Goebell PJ;
Clin Genitourin Cancer; 2017 Apr; 15(2):e209-e215. PubMed ID: 27720164
[TBL] [Abstract][Full Text] [Related]
19. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
